

# Hillard M Lazarus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2950057/publications.pdf>

Version: 2024-02-01

363  
papers

14,503  
citations

31902

53  
h-index

23472

111  
g-index

404  
all docs

404  
docs citations

404  
times ranked

12631  
citing authors

#	ARTICLE	IF	CITATIONS
1	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	1.7	10
2	Consolidation in AML: Abundant opinion and much unknown. <i>Blood Reviews</i> , 2022, 51, 100873.	2.8	5
3	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>t(8;21) KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	2.5	5
4	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 48.e1-48.e10.	0.6	18
5	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	2.5	35
6	Historical perspective and a glance into the antibody-based conditioning regimens: A new era in the horizon?. <i>Blood Reviews</i> , 2022, 52, 100892.	2.8	1
7	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 31-37.	1.3	4
8	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 295-298.	1.3	2
9	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404.	3.4	32
10	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	0.6	3
11	A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 250.e1-250.e8.	0.6	10
12	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 310-320.	0.6	11
13	Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. <i>British Journal of Haematology</i> , 2022, 197, 326-338.	1.2	1
14	Protein Biomarkers in Monocytes and CD4 Lymphocytes for Predicting Lithium Treatment Response of Bipolar Disorder: a Feasibility Study with Tyramine-Based Signal-Amplified Flow Cytometry.. <i>Psychopharmacology Bulletin</i> , 2022, 52, 8-35.	0.0	1
15	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 603.e1-603.e7.	0.6	4
16	G-CSF and GM-CSF Are Different. Which One Is Better for COVID-19?. <i>Acta Haematologica</i> , 2021, 144, 355-359.	0.7	15
17	Liaisons Dangereuses? new drugs, physicians and the drug industry. <i>Bone Marrow Transplantation</i> , 2021, 56, 299-302.	1.3	1
18	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	0.6	15

#	ARTICLE	IF	CITATIONS
19	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	2.0	15
20	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	2.0	12
21	Is G-CSF Dangerous in COVID-19: Why Not Use GM-CSF?. <i>Acta Haematologica</i> , 2021, 144, 350-351.	0.7	9
22	Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation. <i>Blood Reviews</i> , 2021, 47, 100779.	2.8	2
23	New cancer therapies. Are haematopoietic cell transplants a dead duck?. <i>Bone Marrow Transplantation</i> , 2021, 56, 1086-1089.	1.3	3
24	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 264.e1-264.e7.	0.6	13
25	Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?. <i>Blood Reviews</i> , 2021, 46, 100742.	2.8	11
26	Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. <i>Blood Reviews</i> , 2021, 47, 100773.	2.8	63
27	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.	0.6	34
28	Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization. <i>Blood Reviews</i> , 2021, 47, 100771.	2.8	17
29	Graft-Versus-Host Disease (GvHD) Prophylaxis. , 2021, , 153-186.		0
30	Mesenchymal Stromal Cells: Impact on Hematopoietic Cell Transplantation. , 2021, , 859-870.		1
31	DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Seminars in Hematology</i> , 2021, 58, 45-55.	1.8	8
32	Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Older Patients with Active, Relapsed or Refractory (R/R) Acute Myeloid Leukemia Results in Successful and Timely Engraftment Not Related to the Radiation Dose Delivered. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S57-S58.	0.6	0
33	Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 503.e1-503.e8.	0.6	2
34	Myeloablative Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Spares the GI Tract and Has Low Incidence of Severe Mucositis, Febrile Neutropenia and Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML). <i>Transplantation and Cellular Therapy</i> , 2021, 27, S56.	0.6	0
35	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 3291-3305.	0.6	85
36	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Molecular classification improves risk assessment in adult <i>BCR-ABL1</i>-negative B-ALL. <i>Blood</i> , 2021, 138, 948-958.	0.6	59
38	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 410-422.	0.6	13
39	Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 194, 145-157.	1.2	12
40	Role of molecularly-cloned hematopoietic growth factors after acute high-dose radiation exposures. <i>Journal of Radiological Protection</i> , 2021, 41, S478-S489.	0.6	4
41	Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 309-318.	1.2	10
42	The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 507-516.	0.6	26
43	Invasive fungal disease and the immunocompromised host including allogeneic hematopoietic cell transplant recipients: Improved understanding and new strategic approach with sargramostim. <i>Clinical Immunology</i> , 2021, 228, 108731.	1.4	10
44	Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?. <i>Bone Marrow Transplantation</i> , 2021, 56, 2046-2049.	1.3	4
45	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 679.e1-679.e8.	0.6	10
46	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	0.6	11
47	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	0.6	15
48	Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?. <i>Frontiers in Immunology</i> , 2021, 12, 706186.	2.2	27
49	The impact of cult behavior on haematopoietic cell transplant practices: believers and non-believers. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	1
50	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 993.e1-993.e8.	0.6	4
51	CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. <i>Blood Advances</i> , 2021, 5, 4560-4568.	2.5	12
52	Optimization of Human Mesenchymal Stem Cells for Rheumatoid Arthritis: Implications for Improved Therapeutic Outcomes. <i>ACR Open Rheumatology</i> , 2021, , .	0.9	2
53	Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis. <i>Blood</i> , 2021, 138, 907-907.	0.6	0
54	Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study. <i>Blood</i> , 2021, 138, 413-413.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials. <i>Blood</i> , 2021, 138, 690-690.	0.6	0
56	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 3880-3880.	0.6	4
57	Human Multipotent Adult Progenitor Cells Effectively Reduce Graft-vs-Host Disease While Preserving Graft-Vs-Leukemia Activity. <i>Stem Cells</i> , 2021, 39, 1506-1519.	1.4	4
58	Does a durian smell like a rose? The dangers of jargon. <i>Bone Marrow Transplantation</i> , 2020, 55, 280-282.	1.3	2
59	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	1.3	61
60	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
61	A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 226-233.e1.	0.2	18
62	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
63	Comparison of outcomes of HCT in blast phase of <i>t(9;22) BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	2.5	14
64	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	2.0	47
65	Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. <i>Transfusion</i> , 2020, 60, 1867-1872.	0.8	3
66	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18
67	Microtransplantation for Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2020, 6, 1614.	3.4	7
68	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
69	Roger Herschel Herzig: younger half of the dynamic duo which advanced leukaemia therapy and transplants: January 4, 1946 to July 18, 2020. <i>Leukemia</i> , 2020, 34, 2824-2825.	3.3	0
70	AML-123: Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S182.	0.2	0
71	Bacterial contamination and septic transfusion reaction rates associated with platelet components before and after introduction of primary culture: experience at a US Academic Medical Center 1991 through 2017. <i>Transfusion</i> , 2020, 60, 974-985.	0.8	16
72	At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. <i>British Journal of Haematology</i> , 2020, 191, 37-43.	1.2	9

#	ARTICLE	IF	CITATIONS
73	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 2121-2131.	1.3	7
74	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	2.5	14
75	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	2.5	63
76	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	1.7	23
77	Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT) Followed By Lenalidomide Maintenance for Multiple Myeloma (MM) with or without Vaccination with Dendritic Cell/ Myeloma Fusions (DC/MM fusion) Tj ETQq1 1 0.784314 rgB2/Overlook <i>Myeloma</i> , 2020, 26, 662-669.	1.4	1
78	The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1747-1756.	2.0	7
79	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020, 6, 1011.	3.4	39
80	A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2191-2199.	0.6	4
81	Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. <i>British Journal of Haematology</i> , 2020, 189, 1171-1181.	1.2	58
82	Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 327.	1.3	8
83	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1210-1217.	2.0	4
84	Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020, 190, 822-836.	1.2	53
85	Treatment-related mortality following autologous hematopoietic stem cell transplantation is unaffected by timing of G-CSF administration. <i>Bone Marrow Transplantation</i> , 2020, 55, 1697-1700.	1.3	1
86	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143.	2.0	13
87	Can we prevent or treat graft-versus-host disease with cellular-therapy?. <i>Blood Reviews</i> , 2020, 43, 100669.	2.8	13
88	Peripheral neuropathy in hematologic malignancies – Past, present and future. <i>Blood Reviews</i> , 2020, 43, 100653.	2.8	16
89	Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants. <i>JAMA Dermatology</i> , 2020, 156, 631.	2.0	9
90	Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma – specific venous thrombosis prediction models. <i>American Journal of Hematology</i> , 2020, 95, 918-926.	2.0	8

#	ARTICLE	IF	CITATIONS
91	Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 632-633.	2.0	2
92	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	3.3	27
93	Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. <i>Blood Advances</i> , 2020, 4, 706-716.	2.5	11
94	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	2.5	34
95	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	1.7	51
96	Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	2.0	17
97	High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 30-31.	0.6	2
98	Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered. <i>Blood</i> , 2020, 136, 42-44.	0.6	3
99	Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2020, 136, 33-34.	0.6	0
100	CTNI-49. PHASE I STUDY OF MGMT-P140K TRANSFECTED HEMATOPOIETIC PROGENITOR CELLS COMBINED WITH TMZ/O6BG DOSE ESCALATION FOR NEWLY DIAGNOSED, UNMETHYLATED GLIOBLASTOMA: TOLERANCE AND EVIDENCE OF SURVIVAL BENEFIT. <i>Neuro-Oncology</i> , 2020, 22, ii53-ii53.	0.6	0
101	Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study. <i>Blood</i> , 2020, 136, 24-25.	0.6	1
102	CAR-T "and a side order of IgG, to go?" Immunoglobulin replacement in patients receiving CAR-T cell therapy. <i>Blood Reviews</i> , 2019, 38, 100596.	2.8	109
103	Survival outcomes of allogeneic hematopoietic cell transplants with EBV+ or EBV- post-transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019, 21, e13145.	0.7	22
104	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10
105	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
106	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.	2.0	21
107	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1354-1360.	1.3	19
108	The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). <i>Leukemia Research</i> , 2019, 78, 29-33.	0.4	2

#	ARTICLE	IF	CITATIONS
109	Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2086-2090.	2.0	42
110	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1424-1431.	2.0	14
111	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1099-1106.	2.0	12
112	The pharmacologic management of multiple myeloma in older adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 887-902.	0.9	11
113	SAT0010â€¦FUNCTIONAL BIOMARKER DEVELOPMENT FOR CELL-BASED THERAPY IN RHEUMATOID ARTHRITIS. , 2019, , .		4
114	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89
115	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <i>Blood Advances</i> , 2019, 3, 2525-2536.	2.5	13
116	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	2.5	37
117	A Phase 1/2 Trial of Low-Dose Continuous Azacitidine in Combination with Lenalidomide and Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e262-e263.	0.2	0
118	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
119	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.	1.3	47
120	Allogeneic hematopoietic cell transplantation; the current renaissance. <i>Blood Reviews</i> , 2019, 34, 34-44.	2.8	67
121	Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. <i>Haematologica</i> , 2019, 104, e147-e150.	1.7	4
122	Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 73-82.	0.2	1
123	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. <i>American Journal of Hematology</i> , 2019, 94, 111-117.	2.0	21
124	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
125	Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial. <i>Blood</i> , 2019, 134, 5642-5642.	0.6	3
126	Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 1309-1309.	0.6	9



#	ARTICLE	IF	CITATIONS
127	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. <i>Blood</i> , 2019, 134, 115-115.	0.6	19
128	A phase I study of MGMT-P140K transfected hematopoietic progenitor cells (HPC) combined with TMZ/O6BG dose escalation for newly diagnosed, MGMT unmethylated glioblastoma: Tolerance and evidence of survival benefit.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2062-2062.	0.8	5
129	Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731876528.	0.5	7
130	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	2.0	61
131	Anti-cancer vaccine therapy for hematologic malignancies: An evolving era. <i>Blood Reviews</i> , 2018, 32, 312-325.	2.8	19
132	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 945-955.	2.0	7
133	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.	2.0	2
134	Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 501-511.	1.4	86
135	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
136	Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. <i>Blood Reviews</i> , 2018, 32, 106-115.	2.8	40
137	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 175-184.	2.0	7
138	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
139	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
140	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma. <i>Cancer</i> , 2018, 124, 816-825.	2.0	44
141	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. <i>Blood Advances</i> , 2018, 2, 1198-1206.	2.5	21
142	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	2.5	35
143	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	2.5	27
144	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11

#	ARTICLE	IF	CITATIONS
145	Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 3379-3379.	0.6	1
146	Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes. <i>Blood</i> , 2018, 132, 5754-5754.	0.6	0
147	Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes. <i>Blood</i> , 2018, 132, 4627-4627.	0.6	0
148	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. <i>Cancer</i> , 2017, 123, 2035-2042.	2.0	14
149	Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1320-1326.	2.0	10
150	Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1327-1334.	2.0	38
151	Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. <i>Leukemia Research</i> , 2017, 59, 55-64.	0.4	17
152	Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia. <i>Pediatric Transplantation</i> , 2017, 21, e12870.	0.5	5
153	Autologous hematopoietic cell transplantation for adult acute myeloid leukemia: An obsolete or resurfacing concept?. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 327-332.	0.7	9
154	Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 245-261.	1.1	42
155	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. <i>Haematologica</i> , 2017, 102, 1823-1832.	1.7	43
156	Immunophenotypic and molecular comparison between allogeneic and autologous graft-versus-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1087-1091.	0.7	2
157	Notch2 blockade enhances hematopoietic stem cell mobilization and homing. <i>Haematologica</i> , 2017, 102, 1785-1795.	1.7	19
158	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	0.6	210
159	Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making. <i>Expert Review of Hematology</i> , 2017, 10, 563-574.	1.0	22
160	Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 42-49.	2.0	46
161	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
162	Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. <i>Journal of Cancer</i> , 2017, 8, 1009-1017.	1.2	5

#	ARTICLE	IF	CITATIONS
163	Venous thromboembolism (VTE) in multiple myeloma (MM) patients undergoing autologous hematopoietic cell transplantation (HCT).. Journal of Clinical Oncology, 2017, 35, e19503-e19503.	0.8	0
164	Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment. Stem Cells International, 2016, 2016, 1-12.	1.2	117
165	Midostaurin: an emerging treatment for acute myeloid leukemia patients. Journal of Blood Medicine, 2016, 7, 73.	0.7	48
166	Favorable outcome to glucocorticoid therapy for engraftment syndrome in pediatric autologous hematopoietic cell transplant. Pediatric Transplantation, 2016, 20, 297-302.	0.5	6
167	Pediatricâ€inspired therapy compared to allografting for <scp>P</scp>hiladelphia chromosomeâ€negative adult ALL in first complete remission. American Journal of Hematology, 2016, 91, 322-329.	2.0	72
168	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer, 2016, 122, 3005-3014.	2.0	45
169	Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation. British Journal of Haematology, 2016, 174, 235-248.	1.2	115
170	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica, 2016, 101, 1426-1433.	1.7	53
171	Development of a Functional Biomarker for Use in Cell-Based Therapy Studies in Seropositive Rheumatoid Arthritis. Stem Cells Translational Medicine, 2016, 5, 628-631.	1.6	4
172	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. Biology of Blood and Marrow Transplantation, 2016, 22, 1543-1551.	2.0	42
173	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood, 2016, 127, 938-947.	0.6	246
174	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood, 2016, 127, 2427-2438.	0.6	403
175	Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. Journal of Clinical Oncology, 2016, 34, 3544-3553.	0.8	99
176	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1636-1645.	2.0	71
177	Post-Transplant Outcomes in High-Risk Compared with Nonâ€High-Risk Multiple Myeloma: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1893-1899.	2.0	34
178	Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood, 2016, 127, 496-502.	0.6	165
179	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood, 2016, 128, 2561-2567.	0.6	174
180	Early Passage Dependence of Mesenchymal Stem Cell Mechanics Influences Cellular Invasion and Migration. Annals of Biomedical Engineering, 2016, 44, 2123-2131.	1.3	7

#	ARTICLE	IF	CITATIONS
181	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 520-527.	2.0	14
182	Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes. <i>British Journal of Haematology</i> , 2016, 173, 404-412.	1.2	12
183	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
184	Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart's content. <i>Blood Reviews</i> , 2016, 30, 169-178.	2.8	15
185	Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age ≥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. <i>Blood</i> , 2016, 128, 339-339.	0.6	7
186	Low Dose Antithymocyte Globulin (ATG) for Graft-Versus-Host Disease (GVHD) Prophylaxis. <i>Blood</i> , 2016, 128, 5788-5788.	0.6	1
187	Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 679-679.	0.6	3
188	Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma Patients: Risk Factors and Outcomes. <i>Blood</i> , 2016, 128, 3611-3611.	0.6	0
189	Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children. <i>Blood</i> , 2016, 128, 664-664.	0.6	1
190	A Phase I Dose Finding Trial of Eltrombopag during Consolidation Therapy in Adults with Acute Myeloid Leukemia Employing a Unique Dosing Design: PrE0901, a Precog Study. <i>Blood</i> , 2016, 128, 4053-4053.	0.6	1
191	Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance. <i>Clinical Transplantation</i> , 2015, 29, 851-857.	0.8	11
192	Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
193	Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1815-1822.	2.0	13
194	A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 428-432.e2.	0.2	68
195	New Cancers after Autotransplantations for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 738-745.	2.0	33
196	Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase 1 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 720-728.	2.0	56
197	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
198	The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1251-1257.	2.0	14

#	ARTICLE	IF	CITATIONS
199	Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1926-1931.	2.0	7
200	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
201	Double Umbilical Cord Blood Transplantation: Relevance of Persistent Mixed-Unit Chimerism. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 612-619.	2.0	18
202	Cutaneous Malignant Neoplasms in Hematopoietic Cell Transplant Recipients. <i>JAMA Dermatology</i> , 2015, 151, 775.	2.0	46
203	Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1046-1053.	2.0	133
204	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	0.8	163
205	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1830-1838.	2.0	12
206	Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 335-341.	2.0	64
207	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 151-158.	2.0	49
208	Race and Ethnicity Influences Collection of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 165-171.	2.0	26
209	Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma. Incidence, Risk Factors and Outcomes. <i>Blood</i> , 2015, 126, 3968-3968.	0.6	0
210	in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993. <i>Blood</i> , 2015, 126, 795-795.	0.6	0
211	Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience. <i>Blood</i> , 2015, 126, 1315-1315.	0.6	0
212	Survival Improvements in Adolescents and Young Adults after Myeloablative Allogeneic Transplantation for Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 829-836.	2.0	43
213	Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1819-1827.	2.0	43
214	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
215	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803.	2.0	73
216	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.	2.0	119

#	ARTICLE	IF	CITATIONS
217	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
218	Allotransplantation for Patients Age $\geq$ 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
219	Avascular Necrosis of Bone after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 587-592.	2.0	33
220	Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1418-1425.	2.0	40
221	Increased Risk of Venous Thromboembolism in Primary Central Nervous System Lymphoma Patients Undergoing Therapy. <i>Blood</i> , 2014, 124, 5431-5431.	0.6	3
222	Salvage Second Hematopoietic Cell Transplantation in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.	2.0	98
223	Prevalence of Hematopoietic Cell Transplant Survivors in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1498-1501.	2.0	210
224	New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2013, 20, 93-99.	1.2	11
225	Improving Survival in Acute Myeloid Leukemia: Pick the Best Subjects?. <i>Journal of Clinical Oncology</i> , 2013, 31, 3854-3856.	0.8	5
226	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i> , 2013, 121, 197-206.	0.6	123
227	The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. <i>Haematologica</i> , 2013, 98, 945-952.	1.7	54
228	Diagnosis and treatment of graft-versus-host disease. , 2013, , 311-329.		1
229	Older Age, Use Of Myeloablative Regimens For Malignant Diseases and Chronic Graft-Versus-Host Disease Are Risk Factors For Avascular Necrosis Of Bone After Allogeneic Hematopoietic Cell Transplantation In Children and Adolescents. <i>Blood</i> , 2013, 122, 917-917.	0.6	1
230	Phase I study of midostaurin and azacitidine in relapsed and elderly AML. <i>Journal of Clinical Oncology</i> , 2013, 31, 7058-7058.	0.8	2
231	Cutaneous complications in hematopoietic cell transplant recipients: Impact of biopsy on patient management.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7036-7036.	0.8	1
232	Low CD34 Cell Dose Is Associated With Higher Non-Relapse and Overall Mortality After Reduced Intensity Conditioning Hematopoietic Cell Transplantation For Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2013, 122, 3342-3342.	0.6	0
233	Stratification Of CLL By ZAP-70 Expression: Analysis Of Samples From The ECOG-Led Intergroup Trial E2997. <i>Blood</i> , 2013, 122, 4116-4116.	0.6	0
234	Second Umbilical Cord Blood Transplant (UCBT2) In Adult Patients With Engraftment Failure Or Autologous Hematopoiesis After UCBT. <i>Blood</i> , 2013, 122, 2117-2117.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Charlson Comorbidity Index (CCI) and Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Do Not Predict Transplant Related Mortality (TRM) and Post-Transplant Outcomes In Young Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation. <i>Blood</i> , 2013, 122, 4582-4582.	0.6	1
236	Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The CIBMTR. <i>Blood</i> , 2013, 122, 554-554.	0.6	8
237	Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008. <i>Blood</i> , 2013, 122, 63-63.	0.6	0
238	Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2012, 2, 1004-1023.	7.7	80
239	Acute leukemia in adults: novel allogeneic transplant strategies. <i>Hematology</i> , 2012, 17, s47-s51.	0.7	7
240	Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 861-873.	2.0	53
241	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. <i>Blood</i> , 2012, 120, 676-676.	0.6	2
242	O6-benzylguanine (BG) and temozolomide (TMZ) therapy of glioblastoma multiforme (GBM) with infusion of autologous lentiviral transduced P140KMGMT+ hematopoietic progenitors to protect hematopoiesis: A phase I study. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS1616-TPS1616.	0.8	0
243	Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study. <i>Blood</i> , 2012, 120, 663-663.	0.6	0
244	Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A CIBMTR Analysis. <i>Blood</i> , 2012, 120, 473-473.	0.6	8
245	Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A CIBMTR Analysis. <i>Blood</i> , 2012, 120, 815-815.	0.6	1
246	When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 382-8.	0.9	8
247	Acute Leukemia. , 2011, , 235-250.		0
248	Spontaneous Autologous Graft-versus-Host Disease in Plasma Cell Myeloma Autograft Recipients: Flow Cytometric Analysis of Hematopoietic Progenitor Cell Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 970-978.	2.0	42
249	Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <i>Blood</i> , 2011, 117, 6963-6970.	0.6	322
250	Is There a Role for ASCT in Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum?. <i>Blood</i> , 2011, 118, 3092-3092.	0.6	1
251	A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL). <i>Blood</i> , 2011, 118, 499-499.	0.6	14
252	Charlson Comorbidity Index (CCI) Not Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Successfully Predicts Transplant Related Mortality and Post-Transplant Outcomes in Elderly Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation. <i>Blood</i> , 2011, 118, 3006-3006.	0.6	0

#	ARTICLE	IF	CITATIONS
253	The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999. Blood, 2011, 118, 2568-2568.	0.6	0
254	Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience. Blood, 2011, 118, 3074-3074.	0.6	0
255	Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,. Blood, 2011, 118, 3619-3619.	0.6	0
256	Reduced Intensity or Non-Ablative Hematopoietic Cell Transplantation in Older Patients with Non-Hodgkin Lymphoma (NHL): Encouraging Survival for Patients ≥55 Years. Blood, 2011, 118, 1015-1015.	0.6	0
257	BEP Versus BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Relapsed Lymphoma. A Single Center Retrospective Review of Two Contemporaneous Cohorts. Blood, 2011, 118, 2019-2019.	0.6	0
258	Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood, 2010, 115, 1850-1857.	0.6	184
259	A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B-Cell Lymphoma: A Report from the CIBMTR. Biology of Blood and Marrow Transplantation, 2010, 16, 35-45.	2.0	88
260	Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood, 2010, 116, 4077-4085.	0.6	188
261	Secondary MGUS After High-Dose Melphalan and Autologous Hematopoietic Progenitor Cell Transplantation In Multiple Myeloma: A Matter of Undetermined Significance.. Blood, 2010, 116, 1296-1296.	0.6	1
262	Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial. Blood, 2010, 116, 169-169.	0.6	13
263	Relationship of Race/Ethnicity and Survival After Single Umbilical Cord Blood Transplantation. Blood, 2010, 116, 224-224.	0.6	2
264	Impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies. Blood, 2010, 116, 2305-2305.	0.6	1
265	The Role of Hematopoietic Cell Transplantation (HCT) for Burkitt Lymphoma: a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood, 2010, 116, 2390-2390.	0.6	1
266	Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT).. Blood, 2010, 116, 3486-3486.	0.6	2
267	Allogeneic Hematopoietic Cell Transplantation (AHCT) for Primary Cutaneous T Cell Lymphoma (CTCL): a Center for International Blood and Marrow Transplant Research (CIBMTR) Review. Blood, 2010, 116, 364-364.	0.6	3
268	Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial. Blood, 2010, 116, 493-493.	0.6	3
269	Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups. Blood, 2010, 116, 524-524.	0.6	6
270	Monosomal Karyotype (MK) In Older Patients with Acute Myeloid Leukemia (AML) on Eastern Cooperative Oncology Group (ECOG) Therapeutic Trials: Poor Prognostic Impact of MK, but Not of Monosomy 7. Blood, 2010, 116, 579-579.	0.6	0



#	ARTICLE	IF	CITATIONS
271	CNS Remission at the Time of Autologous Stem Cell Transplantation Improves Outcome for Patients with Non-Hodgkin's Lymphoma with Pre-Existing CNS Involvement: a CIBMTR Analysis. <i>Blood</i> , 2010, 116, 371-371.	0.6	0
272	Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. <i>Blood</i> , 2010, 116, 680-680.	0.6	0
273	Anthracycline Dose Intensification in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2009, 361, 1249-1259.	13.9	797
274	Rapid Transport and Infusion of Hematopoietic Cells Is Associated with Improved Outcome after Myeloablative Therapy and Unrelated Donor Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 589-596.	2.0	32
275	Defining the Intensity of Conditioning Regimens: Working Definitions. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1628-1633.	2.0	1,419
276	Alternative Donor Hematopoietic Cell Transplantation (HCT) After Reduced Intensity (RIC) or Nonmyeloablative (NST) Conditioning in Advanced Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009, 114, 3380-3380.	0.6	0
277	Comparison of Unrelated and Sibling Donor Allogeneic Hematopoietic Cell Transplantation (HCT) for Follicular Lymphoma (FL) - From the Lymphoma Working Party, European Group for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR).. <i>Blood</i> , 2009, 114, 874-874.	0.6	0
278	Comparison of Twin and Autologous Transplants for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1118-1124.	2.0	28
279	Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1134-1140.	2.0	27
280	Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1323-1333.	2.0	44
281	High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later. <i>Journal of Clinical Oncology</i> , 2008, 26, 2240-2243.	0.8	19
282	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). <i>Blood</i> , 2008, 111, 1827-1833.	0.6	702
283	Relationship between Bacterial Load, Species Virulence, and Transfusion Reaction with Transfusion of Bacterially Contaminated Platelets. <i>Clinical Infectious Diseases</i> , 2008, 46, 1214-1220.	2.9	156
284	Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). <i>Blood</i> , 2008, 112, 3314-3314.	0.6	1
285	Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2008, 112, 459-459.	0.6	1
286	Second Unrelated Donor (URD) Transplant as a Rescue Strategy for 122 Patients with Primary Non Engraftment: Results from the CIBMTR. <i>Blood</i> , 2008, 112, 794-794.	0.6	1
287	Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults. <i>Blood</i> , 2008, 112, 51-51.	0.6	0
288	Donor Characteristics Affecting Graft Failure and Survival after Unrelated Donor Transplantation with Reduced Intensity Conditioning Regimens (RIC) for Hematologic Malignancies.. <i>Blood</i> , 2008, 112, 1968-1968.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Rapid Transport and Infusion of Hematopoietic Stem Cells Can Improve Outcome after Unrelated Donor Transplant.. Blood, 2007, 110, 3063-3063.	0.6	1
290	Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood, 2006, 108, 465-472.	0.6	205
291	Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion, 2006, 46, 719-730.	0.8	84
292	Superior Survival after Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Diffuse Large B-Cell Lymphoma (DLBCL) Not Explained by Differences in Chemosensitivity.. Blood, 2006, 108, 3021-3021.	0.6	6
293	Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an eastern cooperative oncology group trial (E4995). Leukemia and Lymphoma, 2005, 46, 55-61.	0.6	24
294	Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood, 2005, 106, 3760-3767.	0.6	595
295	Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients. Biology of Blood and Marrow Transplantation, 2005, 11, 389-398.	2.0	745
296	Intravenous immunoglobulin: Appropriate indications and uses in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2002, 8, 117-130.	2.0	96
297	Lowering the Prophylactic Platelet Transfusion Threshold: a Prospective Analysis. Leukemia and Lymphoma, 2001, 41, 67-76.	0.6	70
298	Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and Tj ETQq0 0 0,rgBT /Overlock 10 Tt 23-27.	2.0	10
299	Randomized Cross-Over Trial of Progenitor-Cell Mobilization: High-Dose Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor (G-CSF) Versus Granulocyte-Macrophage Colony-Stimulating Factor Plus G-CSF. Journal of Clinical Oncology, 2000, 18, 1824-1830.	0.8	91
300	Clinical Trial: Hematopoietic Progenitor Cell Transplantation in Breast Cancer: Current Status and Future Directions. Cancer Investigation, 1998, 16, 102-126.	0.6	24
301	Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission. New England Journal of Medicine, 1998, 339, 1649-1656.	13.9	569
302	Incidence and outcome of overt gastrointestinal bleeding in patients undergoing bone marrow transplantation. Digestive Diseases and Sciences, 1996, 41, 598-603.	1.1	29
303	Bone Marrow Transplantation in Low-Grade Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1995, 17, 199-210.	0.6	14
304	Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer, 1994, 73, 1716-1720.	2.0	61
305	Renal dysfunction during high-dose cisplatin therapy and autologous hematopoietic stem cell transplantation: Effect of aminoglycoside therapy. American Journal of Medicine, 1993, 94, 497-504.	0.6	13
306	Antimicrobial activity and in vitro corneal epithelial toxicity of antimicrobial agents for Gram-positive corneal pathogens. Current Eye Research, 1993, 12, 603-608.	0.7	8

#	ARTICLE	IF	CITATIONS
307	Kinetics of Erythrogenesis after Bone Marrow Transplantation. American Journal of Clinical Pathology, 1992, 97, 574-583.	0.4	25
308	Fluctuation of serum phenytoin concentrations during autologous bone marrow transplant for primary central nervous system tumors. Journal of Neuro-Oncology, 1992, 12, 25-32.	1.4	15
309	Reticulocyte quantification by flow cytometry, image analysis, and manual counting. Cytometry, 1992, 13, 853-862.	1.8	40
310	Topical fluoroquinolones: Antimicrobial activity and <i>in vitro</i> corneal epithelial toxicity. Current Eye Research, 1991, 10, 557-563.	0.7	51
311	Infusion of High Doses of Undiluted Etoposide Through Central Venous Catheters During Preparation for Bone Marrow Transplantation. Cancer Investigation, 1990, 8, 13-16.	0.6	14
312	An <i>in vitro</i> Analysis of Aminoglycoside Corneal Epithelial Toxicity. Current Eye Research, 1989, 8, 299-304.	0.7	48
313	Vascular graft-associated complement activation and leukocyte adhesion in an artificial circulation. Journal of Biomedical Materials Research Part B, 1987, 21, 379-397.	3.0	43
314	Reptilase for ANLL with DIC. Scandinavian Journal of Haematology, 1986, 36, 411-412.	0.0	0
315	Cyclic parenteral nutrition during bone marrow transplantation in children. Cancer, 1983, 51, 1563-1570.	2.0	20
316	Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer a phase I-II study. Cancer, 1983, 52, 1792-1802.	2.0	125
317	High-dose cytosine arabinoside in the treatment of refractory acute nonlymphocytic leukemia in adults: Results of two six-day regimens. Medical and Pediatric Oncology, 1982, 10, 229-233.	1.0	12
318	Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer, 1982, 49, 1789-1795.	2.0	60
319	Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer, 1981, 48, 2577-2582.	2.0	209
320	Multiple myeloma in young men clinical course and electron microscopic studies of bone marrow plasma cells. Cancer, 1980, 46, 1397-1400.	2.0	34
321	HLA-testing and laboratory medicine. , 0, , 495-510.		0
322	Basic science. , 0, , 3-20.		0
323	Therapeutic decision making in BMT/SCT for acute myeloid leukemia. , 0, , 23-40.		0
324	Therapeutic decision making in BMT/SCT for acute lymphoblastic leukemia. , 0, , 41-56.		0

#	ARTICLE	IF	CITATIONS
325	Therapeutic decision making in BMT/SCT for chronic myeloid leukemia and other myeloproliferative syndromes. , 0 , 57-70.		0
326	Therapeutic decision making in BMT/SCT for chronic lymphatic leukemia. , 0 , 71-84.		0
327	Therapeutic decision making in BMT/SCT for myelodysplasia. , 0 , 85-98.		0
328	Therapeutic decision making in BMT/SCT for non-Hodgkin lymphoma. , 0 , 99-126.		0
329	Therapeutic decision making in BMT/SCT for Hodgkin lymphoma. , 0 , 127-138.		0
330	Therapeutic decision making in hematopoietic stem cell transplantation for multiple myeloma. , 0 , 139-156.		0
331	Therapeutic decision making in BMT/SCT for amyloidosis. , 0 , 157-162.		0
332	Therapeutic decision making in stem cell transplantation for breast cancer. , 0 , 165-168.		0
333	Therapeutic decision making in BMT/SCT for nonseminomatous germ cell tumor of testis (NSGCT). , 0 , 169-176.		0
334	Therapeutic decision making in BMT/SCT for renal cell cancer. , 0 , 177-188.		0
335	Therapeutic decision making in BMT/SCT for soft tissue sarcomas. , 0 , 189-194.		0
336	Therapeutic decision making in BMT/SCT for severe aplastic anemia. , 0 , 197-204.		0
337	Therapeutic decision making in BMT/SCT for congenital immunodeficiencies. , 0 , 205-214.		0
338	Therapeutic decision making in BMT/SCT for hemoglobinopathies. , 0 , 215-226.		0
339	Therapeutic decision making in BMT/SCT for autoimmune disorders. , 0 , 227-232.		0
340	Practical aspects and procedures, including conditioning protocols and haploidentical transplantation. , 0 , 235-300.		0
341	Umbilical cord blood as alternative allogeneic graft source: clinical banking and transplant outcomes. , 0 , 301-310.		0
342	Pathobiology of graft-versus-host disease. , 0 , 313-330.		0

#	ARTICLE	IF	CITATIONS
343	Diagnosis and treatment of graft-versus-host-disease. , 0, , 331-356.		0
344	Management and prophylaxis of infections after BMT/SCT. , 0, , 357-378.		0
345	Organ-related and miscellaneous complications. , 0, , 379-428.		0
346	The BMT/SCT pharmacopoeia. , 0, , 431-492.		0
347	The BMT/SCT pharmacopoeia. , 0, , 411-508.		0
348	Hematopoietic cell transplantation for non-Hodgkin lymphoma. , 0, , 90-112.		0
349	Basic science. , 0, , 7-24.		0
350	Therapeutic decision making in BMT/SCT for acute myeloid leukemia. , 0, , 25-40.		0
351	Therapeutic decision making in BMT/SCT for myelodysplasia. , 0, , 77-89.		0
352	Therapeutic decision making in BMT/ SCT for renal cell cancer. , 0, , 146-158.		0
353	Therapeutic decision making in BMT/SCT for severe aplastic anemia. , 0, , 165-171.		0
354	Therapeutic decision making in BMT/SCT for congenital immunodeficiencies. , 0, , 172-178.		0
355	Therapeutic decision making in BMT/SCT for hemoglobinopathies. , 0, , 179-191.		0
356	HSCT for inborn errors of metabolism and neurodegenerative disorders. , 0, , 192-204.		0
357	Therapeutic decision making in BMT/SCT for autoimmune disorders. , 0, , 205-208.		0
358	Cellular therapy. , 0, , 209-234.		0
359	Umbilical cord blood as an alternative allogeneic graft source: clinical banking and transplant outcomes. , 0, , 288-296.		0
360	Pathobiology of graft-versus-host disease. , 0, , 297-310.		0

#	ARTICLE	IF	CITATIONS
361	Management and prophylaxis of infections after BMT/SCT. , 0, , 330-347.		0
362	HLA-testing and laboratory medicine. , 0, , 509-524.		0
363	Hematopoietic cell transplantation: past, present, and future. , 0, , 1-6.		0